FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 303:485-489 August 28, 1980 Number 9 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

It has been suggested that the reported association between estrogen use and endometrial cancer may have been biased because estrogens provoke uterine bleeding in women with otherwise asymptomatic disease. To evaluate this hypothesis we compared 149 patients with endometrial cancer and 402 control subjects with other conditions with reference to the time when they had last used conjugated estrogens. In women who had last used conjugated estrogens two or more years previously and who had taken them for at least five years, the rate-ratio estimate was 3.3 (95 per cent confidence interval, 1.4 to 8.0) relative to women who had never used them. Uterine bleeding, and hence the diagnosis of otherwise asymptomatic cancer, cannot be attributed to estrogen use that ceased in the distant past. Our results suggest that such use has a residual effect on the risk of endometrial cancer; this effect is not accounted for by biased selection of cases according to estrogen use.

This article has been cited by other articles:

• Adams, B. D., Furneaux, H., White, B. A. (2007). The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-{alpha} (ER{alpha}) and Represses ER{alpha} Messenger RNA and Protein Expression in Breast Cancer Cell Lines. Mol. Endocrinol. 21: 1132-1147 [Abstract] [Full Text]  
• Hale, G. E., Hughes, C. L., Cline, J. M. (2002). Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones. J. Clin. Endocrinol. Metab. 87: 3-15 [Abstract] [Full Text]  
• Feeley, K M, Wells, M (2001). Hormone replacement therapy and the endometrium. J. Clin. Pathol. 54: 435-440 [Abstract] [Full Text]  
• Belchetz, P. E. (1994). Hormonal Treatment of Postmenopausal Women. NEJM 330: 1062-1071 [Full Text]  
• Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B., Ernster, V. L., Cummings, S. R. (1992). Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women. ANN INTERN MED 117: 1016-1037 [Abstract]  
• JUDD, H. L., MELDRUM, D. R., DEFTOS, L. J., HENDERSON, B. E. (1983). Estrogen Replacement Therapy: Indications and Complications. ANN INTERN MED 98: 195-205 [Abstract]  
• Rosenberg, L., Shapiro, S., Slone, D., Kaufman, D. W., Helmrich, S. P., Miettinen, O. S., Stolley, P. D., Rosenshein, N. B., Schottenfeld, D., Engle, R. L. Jr (1982). Epithelial Ovarian Cancer and Combination Oral Contraceptives. JAMA 247: 3210-3212 [Abstract]  
• Hayden, G. F., Kramer, M. S., Horwitz, R. I. (1982). The Case-Control Study: A Practical Review for the Clinician. JAMA 247: 326-331 [Abstract]  
• Horwitz, R. I., Feinstein, A. R., Vidone, R. A., Sommers, S. C., Robboy, S. J. (1981). Histopathologic Distinctions in the Relationship of Estrogens and Endometrial Cancer. JAMA 246: 1425-1427 [Abstract]